Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

Topline B-UP data including a B-OM update are both for unmet medical need and due first giving share price a nice boost. P is in a more crowded space then it was a couple years ago but any sub par news would take focus off B and not be viewed good by the poopoo'ers. Luckily P2B for my money is less risky since it's dove tailing off the P2A 200mg data which saw greater improvement in that arm. I believe this ongoing dose escalation study will be seen as very good and kick this thing onto the Nasdaq.